Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 1034 Neoplasms 815 Carcinoma, Non-Small-Cell Lung 799 Prostatic Neoplasms 621 Colorectal Neoplasms 529 Lung Neoplasms 486 Neoplasm Metastasis 434 Multiple Myeloma 395 Leukemia, Myeloid, Acute 391 Ovarian Neoplasms 334 Pancreatic Neoplasms 316 Melanoma 297 Squamous Cell Carcinoma of Head and Neck 268 Recurrence 256 Carcinoma, Hepatocellular 250 Glioblastoma 238 Brain Neoplasms 237 Triple Negative Breast Neoplasms 213 Carcinoma, Renal Cell 209 Head and Neck Neoplasms 208 Precursor Cell Lymphoblastic Leukemia-Lymphoma 201 Lymphoma 201 Stomach Neoplasms 197 Endometrial Neoplasms 189 Uterine Cervical Neoplasms 185 Lymphoma, Non-Hodgkin 180 Glioma 180 Sarcoma 179 Lymphoma, Large B-Cell, Diffuse 167 Hematologic Neoplasms 162

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Anal Cancer Metastatic × 90 days × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡